Javadi Alireza 4

What Happened

• Alireza Javadi, Chief Technical Officer of Rani Therapeutics (RANI), was granted an award on 2026-06-03 covering 805,500 derivative shares. The reported acquisition price is $0.00, so no cash was exchanged in the grant. This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (filed within the typical two-business-day window).
• Grant: 805,500 derivative shares at $0.00 per share (code A — award/grant).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Vesting (footnote): The award vests 1/48th monthly over four years beginning April 1, 2026, subject to continued service under the company’s 2021 Equity Incentive Plan.
• No indication of a 10b5-1 plan, sale, exercise-for-cash, or tax-withholding reported in the provided data.

Context

• This is a standard compensation grant to an executive and does not represent an open-market buy or sale. The award is subject to multi-year vesting, so it does not provide immediate liquidity or indicate an immediate change in share ownership available to sell.